The Regulatory Landscape
Hemp-derived CBD containing no more than 0.3% delta-9 THC remains federally legal under the 2018 Farm Bill framework. But new legislation enacted in late 2025 is dramatically narrowing what qualifies as "legal hemp," creating what the industry has dubbed the "Hemp Cliff."
What Changes on November 12, 2026
- Total THC standard: The measurement shifts from delta-9 THC only to "total THC" (including THCA). Products must contain no more than 0.3% total THC.
- Per-container cap: A nationwide limit of 0.4 mg of total THC per finished product container—regardless of serving size or product format.
- Synthetic cannabinoid ban: Compounds created through chemical conversion (delta-8 THC, delta-10 THC, HHC) will be reclassified as controlled substances.
FDA Enforcement
The FDA maintains that CBD cannot be lawfully marketed as a conventional food or dietary supplement because it is an active ingredient in FDA-approved drug Epidiolex. However, the agency has adopted limited enforcement discretion for certain orally administered CBD products under a specific CMS pilot program for Medicare patients.
The FDA continues to prioritize enforcement against companies making unauthorized therapeutic claims.
What Businesses Should Do Now
- Audit product portfolios against the upcoming total THC and per-container limits
- Obtain updated COAs that report "total THC" rather than just delta-9
- Review marketing materials for any health or therapeutic claims that could trigger enforcement
- Monitor state laws, as some states have already enacted stricter standards that preempt federal minimums
Looking Ahead
The FDA has submitted a "CBD Products Compliance and Enforcement Policy" to the White House for review, suggesting a more formal framework is in development. Until then, businesses must navigate significant regulatory uncertainty while preparing for the November deadline.
Cannabis Rescheduling Updates 2026: What the Schedule III Move Means for...
May 27, 2026